Today, the Office of the United States Trade Representative, the Department of Commerce, and the Department of Health and Human Services issued the following statements announcing an agreement in principle on pharmaceutical pricing between the United States and the United Kingdom. In the historic U.S.-U.K. Economic Prosperity Deal (EPD), President Trump and Prime Minister Starmer agreed to address long-standing imbalances in U.S.-U.K. pharmaceutical trade by improving the overall environment for pharmaceutical companies operating in the United Kingdom. The EPD also secured continued investment by U.K. pharmaceutical ... (full story)

The Office of the United States Trade Representative (USTR) announced in a statement on Monday that Washington reached an agreement in principle on pharmaceutical pricing with the United Kingdom. London will "reverse the decade-long trend of declining National Health Service (NHS) expenditures on innovative, life-saving medicines, and increase the net price it pays for new medicines by 25%," the USTR office detailed, adding that the UK will also make sure that higher prices for new medicines are not "materially eroded by a demand for portfolio-wide concessions under the Voluntary Scheme for Branded Medicines ... (full story)